News & Blog

GC Therapeutics Advances Cell Programming with Systematic Discovery of Transcription Factor Combinations

PRO-101: study design and interim results from a Phase 1 study to evaluate the safety, tolerability, PK, and PD of prosetin in ALS

MEC Newsletter: Q1 2025 – Biotech’s Next Chapter: What We Learned at Stanford—and Why Unity Is the New Imperative

Aspen Neuroscience Announces 6-Month ASPIRO Phase 1/2a Clinical Trial Results of Personalized Cell Therapy for Parkinson’s Disease

Aspen Neuroscience to Present at the International Society for Gene & Cell Therapy (ISCT) Annual Meeting

SonoThera™ to Present New Data at ASGCT 2025 Demonstrating the Potential of Genetic Medicine Using Targeted, Ultrasound-Mediated Delivery in Treating Duchenne Muscular Dystrophy and Hemophilia A

GC Therapeutics Expands Leadership Team with Industry Veterans Kai-Hsin Chang and Azadeh Golipour

SonoThera Presents New Data at the 2025 MDA Conference Demonstrating the Potential of Genetic Medicine Using Targeted, Ultrasound-Mediated Delivery (UMD) in Treating Duchenne Muscular Dystrophy

MEC Newsletter: 2024 Year-End Retrospective – A Year of Materiality, A Year of Progress

David P. King joins Truvian’s Advisory Board